My watch list
my.bionity.com  
Login  

17 Current news about the topic superoxide dismutase

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
How bacteria exploit a chink in the body's armor

23-Jan-2017

Scientists have discovered how a unique bacterial enzyme can blunt the body's key weapons in its fight against infection. Researchers at the University of Illinois at Urbana-Champaign and Newcastle University in the U.K. are investigating how infectious microbes can survive attacks by the body's ...

more

Guarana found to have higher antioxidant potential than green tea

24-Aug-2016

The millions of people who consume green tea all over the world benefit from the catechins it contains. Catechins are a class of chemical compounds with anti-oxidant and anti-inflammatory properties, among other healthy ingredients. Researchers at the University of São Paulo's Public Health ...

more

Apeiron initiates clinical study to investigate prevention of radiation-induced skin damage in breast cancer patientes

29-Feb-2012

Apeiron Biologics AG announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Apeiron announced that a clinical trial has started with a liposomal topical ...

more

Apeiron acquires rights to new clinical stage project

09-Nov-2010

APEIRON Biologics AG announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD). SOD, a naturally occurring enzyme with important, ...

more

Researchers discover genetic link between both types of ALS

07-May-2010

Researchers from Northwestern University Feinberg School of Medicine have discovered a link between sporadic and familial forms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease also known as Lou Gehrig's disease. Researchers found that a protein called FUS forms ...

more

Tiny particles can deliver antioxidant enzyme to injured heart cells

17-Nov-2009

Researchers at Emory University and the Georgia Institute of Technology have developed microscopic polymer beads that can deliver an antioxidant enzyme made naturally by the body into the heart. Injecting the enzyme-containing particles into rats' hearts after a simulated heart attack reduced the ...

more

UMMS researchers isolate first 'neuroprotective' gene in patients with amyotrophic lateral sclerosis

Genetic variant associated with an increase in survival by 14 months

13-May-2009

A genetic variant that substantially improves survival of individuals with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been indentified by a consortium of researchers led by John Landers, PhD, Associate Professor of Neurology and Robert Brown, MD, DPhil, Chair and ...

more

Amorfix successfully completes ALS drug discovery program

Amorfix Also Achieves Third and Final Milestone Under Biogen Idec Agreement

28-Nov-2008

Amorfix Life Sciences announced that it has achieved the third and final milestone under the 2006 research, investment and option agreement with Biogen Idecto discover novel treatments for amyotrophic lateral sclerosis (ALS - Lou Gehrig’s disease). “The successful completion of the research ...

more

Amorfix Life Sciences and Dr. Cashman receive Canadian government grant to develop treatments for Alzheimer's disease

24-Jul-2008

Amorfix Life Sciences and the University of British Columbia (UBC) announced a research collaboration to develop Alzheimer's treatments based upon the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer's Disease. The research will be aimed at ...

more

ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million

07-Apr-2008

Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced the completion of the sale of ActivBiotics intellectual property assets for $3.5 million. The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a library of novel rifamycin compounds, and 3) a ...

more

Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE